Nielsen 2026 — Dapiglutide Proof-of-Concept Trial for Obesity

EClinicalMedicine·January 1, 2026

Casper K. Nielsen, Thorir G. Pálsson, Julie L. Forman, et al.

Summary

Dapiglutide was evaluated as a dual GLP-1 and GLP-2 receptor agonist for body-weight reduction in a human proof-of-concept trial.

Study Details

Study Design

Randomized double-blind placebo-controlled parallel-group proof-of-concept trial

Indication

Obesity

Intervention

Dapiglutide dual GLP-1/GLP-2 receptor agonist vs placebo

Species

Human